Geftib Tablet
Prescription Required
Product introduction
Geftib Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.
Geftib Tablet is used to treat different types of cancer
Geftib Tablet is used to treat different types of cancer
Uses of Geftib Tablet
Benefits of Geftib Tablet
In Non-small cell lung cancer
Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Geftib Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Side effects of Geftib Tablet
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Geftib
- Diarrhea
- Dry skin
- Loss of appetite
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weakness
- Weight loss
How to use Geftib Tablet
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Geftib Tablet may be taken with or without food, but it is better to take it at a fixed time.
Safety advice
Alcohol
UNSAFE
It is unsafe to consume alcohol with Geftib Tablet.
Pregnancy
CONSULT YOUR DOCTOR
Geftib Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Breast feeding
CONSULT YOUR DOCTOR
Geftib Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Driving
UNSAFE
Geftib Tablet may cause side effects which could affect your ability to drive.
Geftib Tablet may make you feel weak. This may affect your driving ability.
Geftib Tablet may make you feel weak. This may affect your driving ability.
Kidney
CAUTION
Geftib Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Geftib Tablet may be needed. Please consult your doctor.
Liver
SAFE IF PRESCRIBED
Geftib Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Geftib Tablet may not be needed in these patients. Please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Geftib Tablet
₹143.67/Tablet
Geftinat 250mg Tablet
Natco Pharma Ltd
₹196.67/tablet
37% costlier
Geftistar 250mg Tablet
Lupin Ltd
₹123.03/tablet
14% cheaper
Chemogef 250mg Tablet
Neon Laboratories Ltd
₹98/tablet
32% cheaper
Emfib 250mg Tablet
Emcure Pharmaceuticals Ltd
₹308.1/tablet
114% costlier
Geficad Tablet
Cadila Pharmaceuticals Ltd
₹437.41/tablet
204% costlier
Quick tips
- Geftib Tablet helps treat non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
- Take it with or without food, preferably at the same time each day.
- Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after taking this medicine.
- Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
- Inform your doctor if you develop ulceration in your mouth, changes in your vision or if you experience a worsening cough, shortness of breath, or breathing difficulties while taking this medicine.
- Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.
Fact Box
Chemical Class
Quinazolinamines
Habit Forming
No
Therapeutic Class
ANTI NEOPLASTICS
Action Class
Tyrosine kinase inhibitors
Patient concerns
User feedback
Patients taking Geftib Tablet
Once A Day
85%
Once A Week
8%
Twice A Day
8%
What are you using Geftib Tablet for?
Others
67%
Small cell lu*
33%
*Small cell lung cancer
How much was the improvement?
Excellent
67%
Average
33%
What were the side-effects while using Geftib Tablet?
Vomiting
33%
Weakness
33%
Diarrhoea
33%
How do you take Geftib Tablet?
With or witho*
100%
*With or without food
Please rate Geftib Tablet on price
Average
100%
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1734-35.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 616-17.
- Gefitinib. Luton, Bedfordshire: AstraZeneca UK Limited; 2009 [revised 23 Apr. 2018]. [Accessed 232 Jan. 2019] (online) Available from:
- Drugs.com. Gefitinib Pregnancy and Breastfeeding Warnings. [Accessed 27 Mar. 2019] (online) Available from:
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Gefitinib. [Updated 2018 Dec 3]. [Accessed 18 Feb. 2020] (online) Available from:
- Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:
Marketer details
Name: Glenmark Pharmaceuticals Ltd
Address: Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.
Country of origin: India
Lab tests offered by us
Related/Popular tests
523 people viewed this recentlyMRP
₹4309.96
Inclusive of all taxes
30.0 tablets in 1 strip
SOLD OUT
Variants (2)
Notify me